Groundbreaking Gene Editing Trial for Rare Metabolic Disorder

Strategic Insights -

The University of Connecticut Health Center, in collaboration with Connecticut Children's, has achieved a historic milestone by dosing a patient in a groundbreaking clinical trial using gene editing technology to treat glycogen storage disease type 1a (GSD1a), a rare inherited metabolic disorder. This trial marks the third "first-in-human" trial for GSD1a conducted by this research team and represents a beacon of hope for patients and families worldwide. The therapy uses permanent gene editing, one of the most novel technologies in modern medicine, to correct a single nucleotide mutation that causes the disease.

Key Takeaways:

  • The trial is evaluating a therapy that uses CRISPR-Cas genetic editing technology to correct a single nucleotide mutation that causes GSD1a.
  • The therapy is the first of its kind to be tested in humans for GSD1a and has the potential to provide lifelong correction of the disease.
  • The trial is being led by Rebecca Riba-Wolman, MD, a pediatric endocrinologist and physician-scientist at Connecticut Children's and UConn Health.
  • The therapy is based on nucleotide editing and has been made possible through the collaboration between UConn Health, Connecticut Children's, and Beam Therapeutics.
  • The trial has generated excitement among researchers and patients, with many families following the progress of the gene editing mouse studies that laid the foundation for this moment.
  • The trial builds on decades-long leadership in GSD1a research and is expected to help shape the future of treatment not just for this rare condition, but for all genetic diseases.

Statistics:

  • This is the third "first-in-human" trial for GSD1a conducted by this research team.
  • The therapy uses permanent gene editing, one of the most novel technologies in modern medicine.
  • The trial is being led by 4 people, including Rebecca Riba-Wolman, MD, Karen Loechner, MD, Ph.D., and Malaya Mount, MS, RD.
  • The therapy has been made possible through the collaboration between UConn Health, Connecticut Children's, and Beam Therapeutics.
  • The trial has the potential to provide lifelong correction of the disease.

Sources:

  • US State of Connecticut (https://www.portal.ct.gov/-/media/-/Portal/Departments/DHHS/Pages/Governor-Lamont-Announces-History-Making-Gene-Editing-Trial-begins-at-UConn-Health_cbiw.pdf)
  • UConn Health (https://health.uconn.edu/pediatrics/clinical-trials/gene-editing-treatment-possible-for-rare-metabolic-disease/)
  • Connecticut Children's (https://www.connecticutchildrens.org/research-and-innovation/clinical-trials/gene-editing-treatment-possible-for-rare-metabolic-disease/)